Since the standard diagnostic tool, cystoscopy, has low diagnostic sensitivity in detecting low-grade bladder cancer in addition to being inconvenient and costly for patients, numerous non-invasive urine based tests BTA stat test, nuclear matrix protein 22(NMP22) and urinary cytology have been used [6–8]. This evidence concerns the gene NUMA1 and urinary bladder cancer.